Pharma & Biotech News , from our Global Correspondents
Refine search
Pharmaceutical
The Russian pharmaceutical market is undergoing a large-scale transformation, as the share of foreign drugs is steadily declining due to acceleration of processes of import substitution, reports The Pharma Letter’s local correspondent. 18 June 2024
Biosimilars
The recent US crackdown on Chinese biotech companies marks a significant shift in the global biotechnology landscape, with profound implications for competitive strategies. 18 June 2024
Pharmaceutical
Russia is sharply cutting centralized state purchases of anti-HIV drugs due to the problems with funding and the reduction of supplies to Russia by global drugmakers, reports The Pharma Letter’s local correspondent. 12 June 2024
Generics
Indian generics drugmaker Cadila Pharmaceuticals, together with the Russian investment fund the Russian Direct Investment Fund (RDIF), will invest more than 10 billion roubles ($112 million) in the establishment of a pharmaceutical complex and an injection drug plant in Russia. 11 June 2024
Pharmaceutical
Russian drugmaker Nanolek plans to accelerate its expansion this year by expanding its range and increase of output, paying a particular focus to vaccines, The Pharma Letter’s local correspondent reports. 5 June 2024
Generics
India has become the largest supplier of drugs to the Russian market, overtaking Germany, which had been in the lead for the last two years, reports The Pharma Letter’s Russia correspondent. 4 June 2024
Pharmaceutical
Russia has suspended state purchases of a number of original anti-cancer drugs due to problems associated with sanctions and the ever-growing isolation of the country in the international arena, The Pharma Letter’s local correspondent reports. 29 May 2024
Generics
The drug shortage crisis in the USA, intensified by supply chain disruptions and increased demand, presents a significant opportunity for Indian pharmaceutical companies to offer essential support. 28 May 2024
Pharmaceutical
Russia has registered a new domestic drug, fluorothiazinone, which is intended for the treatment of bacterial infections caused by microorganisms resistant to antibiotics, reports The Pharma Letter’s local correspondent. 28 May 2024
Generics
The Russian government is considering tightening domestic patent legislation, in a move to respond to numerous calls of global drugmakers, which are unhappy with the level of protection of their original drugs in the local market, reports The Pharma Letter’s local correspondent. 22 May 2024
Biotechnology
Given that the USA’s House Committee on Oversight and Accountability held a markup meeting last week on the legislation, it is likely that the USA will pass the BIOSECURE Act (the Act) in December this year. 21 May 2024
Biosimilars
As the Indian pharmaceutical industry is propelled by government initiatives to transition from its traditional focus on generic drug production to the development of high-value, innovative products, domestic pharma majors are advocating for a robust US-India trade partnership. 20 May 2024
Pharmaceutical
Russia has faced with the shortage of oncology drug Uromitexan (mercapto ethane sulphonacid; mesna), for which last deliveries to the country were in the spring of 2023, reports The Pharma Letter’s local correspondent. 15 May 2024
Generics
The Russian Ministry of Health has registered domestic generic of Spinraza (nusinersen), an expensive drug used for the treatment of all types of spinal muscular atrophy (SMA) in children and adults, reports The Pharma Letter’s local correspondent. 14 May 2024
Pharmaceutical
Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by involuntary movements, cognitive decline, and emotional disturbances.1 Recent global prevalence data cites 4.88 per 100,000 persons and an incidence of 0.48 cases per 100,000 person-years.2 13 May 2024
Pharmaceutical
As artificial intelligence (AI) and machine learning (ML) continue to revolutionize various industries, the pharmaceutical sector is no exception. Indeed, there has been a substantial surge in drug and biologic submissions incorporating AI/ML components, exceeding 100 submissions in 2021 alone.1 10 May 2024
Pharmaceutical
The US drugmaker Baxter (NYSE: BAX), one of the largest suppliers of dialysis solutions, has suspended its commercial activities in Russia. 8 May 2024
Generics
The level of competition in the Russian market of anti-HIV drugs is tightening, due to the plans of global drugmakers to launch their products and expand their existing portfolios, The Pharma Letter’s local correspondent reports. 1 May 2024
Pharmaceutical
A full cycle of production of a drug for the treatment of Fabry disease will be launched in Russia this year, reports The Pharma Letter’s local correspondent. 30 April 2024
Biosimilars
As over 20 drugs with a combined annual sales value of $250 billion are set to go off-patent, Indian companies have been exhorted to step in with generic and biosimilar versions. 30 April 2024
Generics
India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable. 16 June 2026
Pharmaceutical
Russian drugmaker Pharmstandard plans to build a new complex for the production of live vaccines in the Technopolis special economic zone in the Moscow region, which is expected to be one of the largest of such kind in the country, reports The Pharma Letter’s local correspondent. 15 June 2026
Generics
In a significant move to expand its oncology footprint in the United States, Indian major Dr Reddy’s Laboratories has announced the launch of Bosutinib 400mg tablets, the generic equivalent of Pfizer’s blockbuster drug Bosulif, used in the treatment of chronic myeloid leukemia (CML). 15 June 2026
Generics
Russian pharmaceutical company KhimRar Group is expanding its capacities for the production of active pharmaceutical ingredients (APIs) by 10 times up to 50 tons per year, reports The Pharma Letter’s local correspondent. 8 June 2026
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
Biotechnology
India’s biotechnology sector is entering a transformative phase, with domestic and global players betting on the country’s scientific talent and cost advantages to make advanced therapies such as CAR-T cell therapy more accessible, reports The Pharma Letter’s India correspondent. 1 June 2026
Generics
Indian pharmaceutical companies have pledged an unprecedented $19.1 billion in investments across the USA, marking a watershed moment in bilateral healthcare collaboration. 11 May 2026
Generics
The share of generics in the Russian pharmaceutical market will grow in the coming years, both in the pharmacy segment and in government procurement, according to latest forecasts made by experts of the Russian analyst agency in the field of pharmaceutics DSM Group. 11 May 2026
Generics
Russia is experiencing a boom of sales of obesity drugs, which is mainly due to the recent launch of some domestically developed drugs in this market segment, reports The Pharma Letter’s local correspondent. 8 May 2026
Biotechnology
Russia has faced an acute shortage of Abraxane (paclitaxel), a drug, which is produced by US pharma major Bristol-Myers Squibb and which is designed for the treatment of patients with breast and pancreatic cancer, The Pharma Letter’s local correspondent reports. 5 May 2026
Biotechnology
April 2026 marked a period of cautious progress in rare disease therapeutics. A series of regulatory approvals, research developments, and policy initiatives signalled continued momentum, particularly in pediatric nephrology and oncology. 2 May 2026
Pharmaceutical
Over 500 new drugs are expected to be introduced to the Russian market this year, including through localization, according to recent statements of Russia’s Health Minister Mikhail Murashko. 1 May 2026
Biotechnology
While the geopolitical climate between Washington and Beijing grows increasingly chilled, the Boston-based investor behind the in vivo CAR-T biotech Capstan (acquired by AbbVie) and flu drug developer Cidara (now part of Merck & Co) is choosing to lean in rather than pull away. 1 May 2026
Pharmaceutical
Even as Sun Pharmaceutical Industries edges ahead with its ambitious $13 billion bid to acquire US-based Organon, in what could become the largest overseas acquisition ever attempted by an Indian drugmaker, the move underscores a broader push by Indian pharmaceutical companies to expand their global footprint through strategic acquisitions, reports The Pharma Letter’s India correspondent. 27 April 2026
Generics
Axelpharm, the Russian manufacturer of anticancer generics, may suspend operations due to fines from the local antitrust regulator the Federal Antimonopoly Service (FAS), which were imposed for the company’s participation in patent disputes. 21 April 2026
Pharmaceutical
Russia plans to increase public procurements of anti-cancer drugs that will be part of a new national project, which aims to ensure two-thirds of cancer patients survive five years or more after diagnosis with cancer by 2030, reports The Pharma Letter’s local correspondent. 20 April 2026
Pharmaceutical
The US Food and Drug Administration (FDA) is ramping up government efforts to curb misinformation on prescription drugs that endanger public health. This is in line with the presidential memorandum, which seeks to address misleading direct-to-consumer (DTC) prescription drug advertisements. 20 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Generics
India has moved ahead in developing indigenous capacity for cell and gene therapies, with regulatory bodies issuing national guidelines to ensure safe and ethical deployment of CRISPR-based technologies. 3 April 2026
Biotechnology
March 2026 marked a significant inflection point for rare disease therapeutics, as regulatory momentum, policy pressure, and scientific innovation converged. 30 March 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze